INMUNE BIO INC. - COMM

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

25 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

08 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

28 Mar 2024 15:01:53 By Nasdaq GlobeNewswire

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

26 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

30 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

18 Dec 2023 15:01:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

15 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

01 Nov 2023 15:10:41 By Nasdaq GlobeNewswire

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

30 Oct 2023 08:07:00 By Nasdaq GlobeNewswire